Breast cancer & non-conventional treatments
Despite advances made in conventional cancer treatment for both early and late-stage breast cancer, such treatments have been known to cause severe side effects without offering a curative guarantee.
Breast cancer facts
-
Breast cancer is the most common of all cancers in women and is the leading cause of death from cancer in European women.
-
~332,000 EU women were diagnosed with breast cancer in 2008.
-
1 in 4 breast cancers occur in women under 50.
-
<5% of all breast cancers occur in women younger than 35.
-
1 of 100,000 men is diagnosed with breast cancer per year.
Breast cancer treatment facts
- Breast cancer survival is improving and has doubled in the last 40 years in Europe.
-
~11,400 people die from breast cancer in the UK each year.
-
~691,000 are living with a breast cancer diagnosis in the UK; predicted to rise to 840,000 in 2020.
-
1 in 4 women find the end of treatment the hardest part of breast cancer.
-
1 in 10 breast cancer survivors say they felt ready to move on after end of treatment and hospital discharge.
-
>50% of breast cancer survivors struggle with anxiety at the end of treatment, 31% struggle with depression.
Filling the gap in breast cancer treatment
CAM for breast cancer treatment is one of our most frequently queried topics. To meet patient needs, we have published a patient guide for breast cancer with the support of luxury lingerie company Van de Velde. A print version is available on demand.
Notre vision sur le traitement du cancer
NOTRE PROMESSE
-
Nous investissons dans la recherche scientifique la plus prometteuse pour réaliser des progrès certains dans la lutte contre le cancer. -
Améliorer et prolonger la vie des patients est notre seule cible. Le retour financier ne fait pas partie de nos objectifs. -
Nous identifions des potentiels inexploités dans la recherche sur le cancer qui amèneront des solutions pragmatiques pour les patients dans le besoin. -
Nous cherchons à obtenir un impact et pour ce faire, nous investissons nos ressources là où nous pensons pouvoir réaliser rapidement des progrès. -
Chaque cancer mérite la même attention, indépendamment de critères de prévalence ou de rentabilité.